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1. INTRODUCTION 
 
1.1 SOLID DOSAGE FORMS (1) 
The convenient oral drug delivery has been known for decades is the most 
widely utilized route of administration among all the routes. It remains the preferred 
route of administration in the discovery and development of new drug candidates. 
The popularity of oral route is attributed to patient acceptance, ease of 
administration, accurate dosing, cost effective manufacturing methods and 
generally improve the shelf life of the product (1).  
Oral solid forms such as tablets and capsules has been formulated and 
developed nowadays since they are most effective routes of administration of a new 
drug. Pharmaceutical products designed for oral delivery and currently available on 
the prescription and over the counter markets are mostly the immediate release type, 
which are designed for immediate release of drug for rapid absorption. Many new 
generations of pharmaceutical products called controlled and sustained release drug 
delivery system have also been developed. So the combination of both will be very 
much useful for immediate response and for maintaining the duration of action.   
 
1.2 TABLETS 
Tablet is defined as a compressed solid dosage form containing medicaments 
with or without excipients.  According to the Indian Pharmacopoeia Pharmaceutical 
tablets are solid, flat or biconvex dishes, unit dosage form, prepared by compressing a 
drugs or a mixture of drugs, with or without diluents. They vary in shape and differ 
greatly in size and weight, depending on amount of medicinal substances and the 
intended mode of administration. It is the most popular dosage form and 70% of the 
total medicines are dispensed in the form of tablet. It was prepared by the various 
technique. They are wet granulation, dry granulation and direct compression as shown 
in fig.1.  
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Direct Compression   Dry Granulation  Wet Granulation 
 
Fig.1  Various techniques of Granulation Technology on Large scale (2) 
 
a) Advantages of the Tablet dosage form (3):   
1. They are unit dosage form and offer the greatest capabilities of all oral dosage 
form for the greatest dose precision and the least content variability.   
2. Cost is lowest of all oral dosage form.   
3. Lighter and compact.   
4. Easiest and cheapest to package and strip.   
5. Easy to swallowing with least tendency for hang-up.   
6. Sustained release product is possible by enteric coating.   
7. Objectionable odour and bitter taste can be masked by coating 
technique.   
8. Suitable for large scale production.   
9. Greatest chemical and microbial stability over all oral dosage form.   
10. Product identification is easy and rapid requiring no additional steps when 
employing an embossed and / or monogrammed punch face.   
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 b) Disadvantages of Tablet dosage form:   
1. Difficult to swallow in case of children and unconscious patients.   
2. Some drugs resist compression into dense compacts, Owing to amorphous 
nature, Low density character.   
3. Drugs with poor wetting, Slow dissolution properties, May be difficult to 
formulate or manufacture as a tablet that will still provide adequate or full drug 
bioavailability.   
4. Bitter testing drugs, Drugs with an objectionable odour or drugs that are 
sensitive to oxygen may require encapsulation or coating.   
 
 c) Different types of Tablets (4): 
(i) Tablets ingested orally:   
1. Compressed tablet   
2. Multiple compressed tablets -Compression coated tablet -Layered tablet -
Inlay Tablet   
3. Repeat action tablet   
4. Delayed release tablet   
5. Sugar coated tablet   
6. Film coated tablet   
7. Chewable tablet  
8. Targeted Tablets  
 
(ii) Tablets used in oral cavity:   
1. Buccal tablet   
2. Sublingual tablet   
3. Troches or lozenges   
4. Dental cone   
 
(iii) Tablets administered by other route:   
1. Implantation tablet   
2. Vaginal tablet   
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(iv) Tablets used to prepare solution:   
1. Effervescent tablet   
2. Dispensing tablet   
3. Hypodermic tablet  
4. Tablet triturates 
  
1.3 EXTENDED RELEASE TABLETS (5) 
Drug products designed to reduce the frequency of dosing by modifying the 
rate of drug absorption have been available for many years. Early modified-release 
products were often intramuscular/subcutaneous injections of suspensions of 
insoluble drug complexes, e.g. procaine penicillin, protamine zinc insulin, insulin zinc 
suspensions or injections of the drug in oil, e.g. fluphenazine decanoate. Advances in 
technology have resulted in novel oral modified-release dosage forms.  
Many terms are used to describe modified-release products including 
extended-release, prolonged-release, controlled-release, controlled-delivery, slow-
release and sustained-release. These preparations, by definition, have a reduced rate 
of release of active substance. In general, these terms are interchangeable.  
Delayed-release products are modified-release, but by definition are not 
extended-release. They involve the release of discrete amount(s) of drug sometime 
after drug administration, e.g. enteric-coated products, and exhibit a lag time during 
which little or no absorption occurs.  
While a number of such modified-release products are available as both prescription 
and over-the-counter drugs, only a limited number have been shown to offer a 
therapeutic advantage. Many of the formulations appear to have been developed to 
extend patents or to create a marketing advantage over conventional-release 
products, rather than because of clinical advantage 
• Sustained blood levels  
• Attenuation of adverse effects  
• Improved patient compliance. 
The extent of fluctuation in drug concentration at steady state is determined by 
the relative magnitude of the elimination half-life and the dosing interval. If a drug is 
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given at an interval equal to the elimination half-life, there is a two-fold difference 
between the maximum and minimum concentrations at steady state.  
For drugs with short half-lives and with a clear relationship between 
concentration and response, it will be necessary to dose at regular, frequent intervals 
in order to maintain the concentration within the therapeutic range. Higher doses at 
less frequent intervals will result in higher peak concentrations with the possibility of 
toxicity. For some drugs with wide margins of safety, this approach may be 
satisfactory, e.g. amoxycillin has a half-life of approximately one hour, but a dosage 
frequency of 8 hours. This means that very large fluctuations will occur within a dosing 
interval, but, in view of the low toxicity of this drug, no difficulty with this approach is 
encountered provided the concentrations are above the minimum effective 
concentration during the dosing interval. On the contrary, clinical efficacy may be 
enhanced by the transiently high bactericidal concentration of the antibiotic e.g. 
aminoglycosides.  
Conversely, drugs with long half-lives can be given at less frequent intervals. 
There is generally no advantage in formulating these drugs as extended-release 
formulations unless a rapid rate of change of concentration during the absorptive 
phase is responsible for transient adverse effects. The pharmacological effect of some 
drugs with short half-lives is sustained by various mechanisms: (6)  
• The drug binds to the tissues e.g. tissue-bound ACE inhibitors. For these drugs, 
less frequent dosing is needed even though the drug may have a short half-life  
• the drugs have irreversible effects e.g. the inhibition of platelet cyclo-
oxygenase by aspirin  
• the relationship between response and plasma/blood concentrations is 
relatively flat or if the dose given results in concentrations which are in the 
plateau region of the dose-response relationship e.g. thiazides in hypertension  
• The drug is metabolised to pharmacologically active metabolite(s) which are 
more slowly cleared than the parent drug e.g. quinapril, trandolapril, 
venlafaxine. 
Types of Extended Release Products: 
 Diffusion-controlled products 
 Dissolution-controlled products 
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 Erosion products 
 Osmotic pump systems 
 Ion exchange resins 
 
1.4 HYPERTENSION (7) 
Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long 
term medical condition in which the blood pressure in the articles is persistently 
elevated. High blood pressure usually does not cause symptoms. Long term high blood 
pressure, however, is a major risk factor for coronary artery disease, stroke, heart 
failure, peripheral vascular disease, vision loss, and chronic kidney disease. 
High blood pressure is classified as either Primary (essential) high blood 
pressure or secondary high blood pressure. About 90–95% of cases are primary, 
defined as high blood pressure due to nonspecific lifestyle and genetic factors. 
Lifestyle factors that increase the risk include excess salt, excess body weight, smoking 
and alcohol. The remaining 5–10% of cases are categorized as secondary high blood 
pressure, defined as high blood pressure due to an identifiable cause, such as chronic 
kidney disease, narrowing of the kidney arteries, an endocrine disorder, or the use of 
birth control pills.  
Blood pressure is expressed by two measurements, the systolic and diastolic 
pressures, which are the maximum and minimum pressures, respectively. Normal 
blood pressure at rest is within the range of 100–140 millimeters mercury (mmHg) 
systolic and 60–90 mmHg diastolic. High blood pressure is present if the resting blood 
pressure is persistently at or above 140/90 mmHg for most adults. Different numbers 
apply to children. Ambulatory blood pressure monitoring over a 24-hour period 
appears more accurate than office best blood pressure measurement.  
Lifestyle changes and medications can lower blood pressure and decrease the 
risk of health complications. Lifestyle changes include weight loss, decreased salt 
intake, physical exercise, and a healthy diet. If lifestyle changes are not sufficient then 
blood pressure medications are used. Up to three medications can control blood 
pressure in 90% of people. The treatment of moderately high arterial blood pressure 
(defined as >160/100 mmHg) with medications is associated with an improved life 
expectancy. The effect of treatment of blood pressure between 140/90 mmHg and 
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160/100 mmHg is less clear, with some reviews finding benefit and others finding a 
lack of evidence for benefit. High blood pressure affects between 16 and 37% of the 
population globally. In 2010 hypertension was believed to have been a factor in 18% 
of all deaths (9.4 million globally).  
Hence, in the present study, I have taken the anti-hypertension drug 
metoprolol succinate equivalent to metoprolol tartrate and formulated as extended 
release tablets with swellable polymers such as HPMC K100M, HPMC K4M by wet 
granulation method.  
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2. LITERATURE REVIEW 
1. Ranjani V. Nellore, Gurvinder Singh Rekhi et al., (2008) developed model extended 
release (ER) matrix tablet formulations for metoprolol tartrate (100 mg) sufficiently 
sensitive to manufacturing variables and to serve as the scientific basis for regulatory 
policy development on scale-up and post approval changes for modified-release 
dosage forms (SUPAC-MR). Several grades and levels of hydroxypropyl 
methylcellulose (Methocel K4M, K15M, K100M and K100LV), fillers and binders were 
studied. Three granulation processes were evaluated; direct compression, fluid-bed 
or high-shear granulation. 
 
2. Jaleh Varshosaz, N. Tavakoli et al., (2007) prepared metoprolol tartrate sustained 
release tablets (100 mg) using xanthan/guar gums, HPMC and CMC polymers by direct 
compression method. Results showed that natural gums were suitable for production 
of sustained release tablets of metoprolol. 
 
3. H. Ravishankar, P. Patil et al., (2008) described a modulated release, multiunit oral 
drug delivery technology using a system based on ionic interactions of anions of salts 
with quaternary ammonium ions of the ammoniomethacrylate polymer. The system 
consisted of a drug layered, EUDRAGIT® NE-coated salt core which was further coated 
with EUDRAGIT® RS. The relative effects of different anions on the polymer 
permeability have been investigated by studying their influence on the in vitro drug 
release. 
 
4. Goyal, P. Shukla, A. K. Shrivastav investigated the factors influencing the release 
characteristics of drug substances from hydrophilic polymer matrix tablet using 
various hydrophilic polymers as polyethylene oxide (PEO), hydroxyethyl cellulose 
(HEC) and xanthan gum. Results concluded that best sustained release tablet could be 
produced using PEO along with HEC as hydrophilic controlling polymer. 
 
5. Gothi G.D., Parikh B.N., et al., (2010) made an attempt to reduce the frequency of 
dose administration, to prevent nocturnal heart attack and to improve the patient 
Arulmigu Kalasalingam College of Pharmacy 
Department of Pharmaceutics   9 
Compliance by developing extended release (ER) matrix tablet of Metoprolol 
Succinate. They studied effect of concentration of hydrophilic (Eudragit) on the 
release rate of Metoprolol succinate. 
 
6. Y.S.R. Krishnaiah, R.S. Karthikeyan, et al., (2009) designed oral controlled drug 
delivery systems for highly water-soluble drug, metoprolol tartrate using guar gum as 
a carrier in the form of a three-layer matrix tablet. Matrix tablets containing either 30 
(M1), 40 (M2) or 50% (M3) of guar gum were prepared by wet granulation technique 
using starch paste as a binder. Three-layer matrix tablets of metoprolol tartrate were 
prepared by compressing on both sides of guar gum matrix tablet granules of 
metoprolol tartrate M1, M2 or M3 with either 50 (TL1M1, TL1M2 or TL1M3) or 75 mg 
(TL2M1, TL2M2 or TL2M3) of guar gum granules as release retardant layers. 
 
7. Y.S.R. Krishnaiah, R.S. Karthikeyan, et al., (2008) designed oral controlled drug 
delivery systems for highly water-soluble drugs using guar gum as a carrier in the form 
of three-layer matrix tablets. Trimetazidine dihydrochloride was chosen as a model 
drug because of its high water solubility. The results indicated that guar gum, in the 
form of three-layer matrix tablets, is a potential carrier in the design of oral controlled 
drug delivery systems for highly water-soluble drugs such as trimetazidine 
dihydrochloride.  
 
8. S.M. Al-Saidan, Y.S.R. Krishnaiah, et al., (2009) carried out pharmacokinetic 
evaluation of oral controlled release formulation (guar gum-based three layer matrix 
tablets) containing highly soluble metoprolol tartrate as a model drug. The results of 
the study indicated that guar gum three-layer matrix tablets were able to provide oral 
controlled delivery of highly water-soluble drug such as metoprolol tartrate in 
humans. 
 
9. M. R. Siahi, M. B. Jalali et al., (2010) designed oral controlled drug delivery systems 
for the water soluble drug, verapamil hydrochloride, using natural and semisynthetic 
polymers as carriers in the forms of 1- and 3-layer matrix tablets. 3-layer matrix tablets 
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were prepared by compressing the polymers as release retardant layers on both sides 
of the core containing the drug. 
 
10. Cherng-ju Kim evaluated triple layer, donut-shaped tablets (TLDSTs) for extended 
release dosage forms. TLDSTs were prepared by layering 3 powders sequentially after 
pressing them with a punch. The core tablet consisted of enteric polymers, mainly 
hydroxyl propyl methyl cellulose acetate succinate, and the bottom and top layers 
were made of a water-insoluble polymer, ethyl cellulose. He summarized, a TLDST was 
a good design to obtain zero-order or nearly zeroorder release kinetics for a wide 
range of drug solubilities.  
 
11. M. C. Gohel, S. H. Bariya developed venlafaxine hydrochloride layered tablets 
using xanthan gum in the middle and barrier layers by wet granulation technique. 
Substantial water uptake and gelling of xanthan gum appears to be responsible for 
sustaining drug release. 
 
12. Gohel M.C et al., (2009) fabricated modified release tablet of metoprolol succinate 
using hydroxypropyl methylcellulose (HPMC) and xanthan gum as a matrixing agent. 
A 32 full factorial design was employed for the optimization of formulation. The 
percentage drug released at a given time (Y 60, Y 240 and Y 720) and the time required 
for a given percentage of drugs to be released (t 50%) were selected as dependent 
variables. The in vitro drug dissolution study was carried out in pH 6.8 phosphate 
buffer employing paddle rotated at 50 rpm. The similarity factor (f 2) was calculated 
for selection of best batch considering mean in vitro dissolution data of Seloken® XL 
as a reference profile. It is concluded that the desired drug release pattern can be 
obtained by using a proper combination of HPMC (high gelling ability) and xanthan 
gum (quick gelling tendency). The economy of xanthan gum and faster hydration rate 
favours its use in modified release tablets. The matrix integrity during dissolution 
testing was maintained by using hydroxypropyl methylcellulose.  
 
13. Shishoo C.J et al., (2002) evaluated In vitro - in vivo correlation of modified release 
formulations of theophylline. As part of our ongoing study an experimental modified 
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release capsule formulation, containing theophylline (200 mg) loaded microspheres 
(Formulation F4), was developed, characterised and its in vitro and in vivo 
performance was then compared with that of the three market modified release 
formulations of theophylline (200 mg)- two tablets (Formulations F2 and F3) and one 
capsule (Formulation F1). Formulation F1, F2 and F3 were analysed to find out the best 
market sample with acceptable bioavailability. All the four formulations were 
evaluated for in vitro theophylline release using different dissolution test conditions. 
In vitro studies indicated that only formulation F1 showed pH-dependent drug release 
while the other three formulations, including experimental formulation F4, showed 
almost condition-independent dissolution behaviour. The bioavailability studies 
indicated that amongst the market formulations (F1, F2, and F3), formulation F1 and 
F2 were bioequivalent but F3 failed to demonstrate acceptable dissolution and 
bioavailability.   
 
14. Panchagnula R et al., (2007) studied an in vitro evaluation of modified release 
formulations, marketed in India was conducted and compare their performance with 
a novel matrix- based multi particulate system. The results indicate that even though 
the marketed formulations are found to comply to the definition of modified release 
formulations and predicted to produce therapeutic blood level for a prolonged period 
of time, the fluctuations were expected to be found  uncontrolled expect in the 
osmotic systems and matrix based multi particulate system. Thus it was concluded 
that novel matrix- based multi particulate systems were found to be superior to any 
other marketed formulations with respect to the therapeutic advantage as well as 
manufacturing feasibility.  
 
15. Farrukh Z et al., (2010) evaluated modified-release multiple-unit tablets of 
loratadine and pseudoephedrine hydrochloride. The immediate-release pellets 
containing pseudoephedrine hydrochloride alone or in combination with loratadine 
were prepared using extrusion– spheronization method. The pellets of 
pseudoephedrine hydrochloride were coated to prolong the drug release up to 12 h. 
Both immediate- and prolonged-release pellets were filled into hard gelatin capsule 
and also compressed into tablets using inert tabletting granules of microcrystalline 
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cellulose Ceolus KG-801. The in vitro drug dissolution study conducted using high-
performance liquid chromatography method showed that both multiple-unit capsules 
and multiple-unit tablets released loratadine completely within a time period of 2 h, 
whereas the immediate-release portion of pseudoephedrine hydrochloride was 
liberated completely within the first 10 min of dissolution study. On the other hand, 
the release of pseudoephedrine hydrochloride from the prolonged release coated 
pellets was prolonged up to 12 hr and followed zero-order release kinetic. The drug 
dissolution profiles of multiple-unit tablets and multiple-unit capsules were found to 
be closely similar, indicating that the integrity of pellets remained unaffected during 
the compression process. Moreover, the friability, hardness, and disintegration time 
of multiple-unit tablets were found to be within BP specifications. In conclusion, 
modified release pellet-based tablet system for the delivery of loratadine and 
pseudoephedrine hydrochloride was successfully developed and evaluated.   
 
16. Gohel M. C et al., (2008) evaluated to prepare novel modified release press coated 
tablets of venlafaxine hydrochloride. Hydroxy propyl methylcellulose K4M and 
hydroxy propyl methylcellulose K100M were used as release modifier in core and coat, 
respectively. A 32 full factorial design was adopted in the optimization study. The drug 
to polymer ratio in core and coat were chosen as independent variables. The drug 
release in the first hour and drug release rate between 1 and 12 h were chosen as 
dependent variables. The tablets were characterized for dimension analysis, crushing 
strength, friability and in vitro drug release. The tablets of check point batch were 
subjected to in vitro drug release in dissolution media with pH 5, 7.2 and distilled 
water. The kinetics of drug release was best explained by Korsmeyer and Peppas 
model (anomalous non-Fickian diffusion). The systematic formulation approach 
enabled us to develop modified release venlafaxine hydrochloride tablets.  
 
17. Gohel M. C et al., (1999) studied the preparation of microspheres of diclofenac 
sodium using cross-linked poly (vinyl alcohol) (PVA). A central composite design 
consisting of a two-level full factorial design superimposed on a star design was 
employed for developing the microspheres. The PVA to the drug ratio X1 and amount 
of glutaraldehyde cross-linking agent X2 were chosen as the independent variables. 
Arulmigu Kalasalingam College of Pharmacy 
Department of Pharmaceutics   13 
The time required for 50% drug dissolution t50 in phosphate buffer (pH 7.2) was 
selected as the dependent variable. An optimum polynomial equation was generated 
for the prediction of the response variable t50. Based on the results of multiple linear 
regression analysis and F statistics, it may be concluded that sustained action can be 
obtained when X1 and X2 are kept at high levels. The X1X2 interaction was found to be 
statistically significant. A response surface plot is presented to show the effects of X1 
and X2on t50. The drug release pattern fit the Higuchi model well. A model was 
validated for accurate prediction of the drug dissolution profile with constraints on 
the percentage drug release in the first, fifth, and seventh hours. The data of a selected 
batch were subjected to an optimization study, and an optimal formulation was 
fabricated. Good agreement was observed between the predicted and the observed 
dissolution profiles of the optimal formulation.  
 
18. Gohel M. C et al., (2007) developed modified release tablets of isoniazid using 
hydroxylpropylmethycellulose as a release-controlling agent. The low-viscosity grade 
hydroxylpropylmethycellulose, medium-viscosity grade hydroxylpropylmethy 
cellulose, and high-viscosity grade hydroxylpropylmethycellulose were used to 
prepare the matrix tablets. The tablets are prepared by direct compression, were 
subjected to physical characterization and in vitro drug release studies. The in vitro 
drug release was carried using USP 1 at 50 rpm in 900 ml of acidic dissolution medium 
(pH 1.2) for 2 h, followed by 900 ml of  alkaline dissolution medium (pH 6.8). The 
polymer type did not affect the flow of powder blend and crushing strength of 
isoniazid tablets. The drug release rate was strongly influenced by the type of polymer 
and concentration of polymer. The viscosity grade of hydroxylpropylmethycellulose 
and the drug release was inversely correlated.   
 
19. Sahib M.N et al., (2009) fabricated prednisolone as an oral modified release tablet 
for colonic targeting. Many trials were performed to prepare a satisfactory formula 
using wet granulation method with various additives and coatings. We found that 
lactose as diluents provided the most reasonable relsease for prednisolone among 
other diluents. In addition the formula containing 1 % Eudragit RS PM was the best 
with regard to 100% release of drug in comparison to other concentrations and other 
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retardant types. Avicel was used as a canalising agent and, the result show that the 
formula containing 30%Avicel PH 302 demonstrated faster release. Eudragit S 100 
provided the best release in phosphate buffer, pH 7.4. The effect of present of binding 
agent polyvinylpyrrolidone (PVP) (5%, 10% and 15%) was studied, and the best results 
were obtained with the concentration of 10%. The trials in this study successfully 
formulated prednisolone-modified release tablets (coated matrix) using a wet 
granulation method as a potential colon delivery system.              
 
20. Avramoff  A et al., (2010) evaluated the in-vitro dissolution and in-vivo 
pharmacokinetic profile of a novel two-phase modified-release formulation for 
diltiazem hydrochloride, as a water-soluble drug. The delivery system consisted of two 
tablets inserted into a capsule. Both tablets comprised a coated drug core-matrix. 
Three different formulations were tested for their dissolution profiles both in water 
media and in buffer with a pH of 6.8. These formulations were also evaluated for their 
pharmacokinetic profile in healthy volunteers after single administration of a 240 mg 
dosing addition the in-vivo /in-vitro correlation (IVIVC) was calculated for these 
formulations. The in-vitro characteristics of these formulations demonstrated a 
controlled release profile in both media but with different characteristics, as in 
Formulation 3 where faster dissolution profile obtained in water but slower one in pH 
6.8 buffer. In-vivo the pharmacokinetic profile of these formulations showed that 
arabinogalactan containing formulations achieved plasma levels which allow a once 
daily administration. IVIVC calculation demonstrated that dissolution tested in buffer 
6.8 media better correlates with the percent absorbed in-vivo and the best results 
were achieved with the formulation containing the highest amount of polysaccharide 
in the coating. It is concluded that the developed formulations achieved a controlled 
release profile both in-vitro and in-vivo which are suitable for once-daily 
administration. 
 
21. Gohel M. C et al., (2003) showed the preparation of tartaric acid treated ispaghula 
husk powder for the development of modified release tablets of diltiazem HCl by 
adopting direct compression technique and a 32 full factorial design. The modified 
ispaghula husk powder showed superior swelling and gelling as compared to 
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untreated powder. Addition of compaction augmenting agent such as dicalcium 
phosphate was found to be essential for obtaining tablets with adequate crushing 
strength. In order to improve the crushing strength of diltiazem HCl tablets, to 
modulate drug release pattern, and to obtain similarity of dissolution profiles in 
distilled water and simulated gastric fluid (pH 1.2), modified guar gum was used along 
with modified ispaghula husk powder and tartaric acid. A novel composite index, 
which considers a positive or a negative deviation from an ideal value, was calculated 
considering percentage drug release in 60, 300, and 540 min as dependent variables 
for the selection of a most appropriate batch. Polynomial equation and contour plots 
are presented. The concept of similarity factor (f2) was used to prove similarity of 
dissolution in water and simulated gastric fluid (pH 1.2).  
 
22. Abdelbary G et al., (2008) developed an extended release matrix tablet of 
nicorandil; a freely water soluble drug used in cardiovascular diseases. Chitosan 
(CH)/hyaluronate sodium (HA), pectin (PE) or alginate sodium (AL) interpolymer 
complexes (IPCs) were prepared. The optimum IPCs (CH: HA, 40:60), (CH: PE, 30:70) 
and (CH: AL, 20:80) were characterized by Fourier transform infrared spectroscopy. 
The IPCs were based on electrostatic interactions between protonated amine groups 
of CH and carboxylate groups of HA, PE or AL. Nicorandil matrix tablets were prepared 
using the optimum IPCs, alone or in combination with Imwitor_ 900 K. Evaluations 
such as weight variation, thickness, content uniformity, friability, disintegration and in 
vitro release studies were performed. The tablets showed acceptable 
pharmacotechnical properties and complied with compendial requirements. Results 
of the dissolution studies revealed that formula F11 (CH: AL, 20:80) IPC: Imwitor_ 900 
K, 3:1) could extend drug release >8 h. Most formulae exhibited non-Fickian diffusion 
drug release profiles. When compared to the immediate release Ikorel_ tablet, the 
duration of effective nicorandil therapeutic concentration from formula F11, in 
healthy human volunteers, was significantly (P < 0.05) extended from 4 to 8 h with 
expected lowering in side effects potential.  
 
23. Limmatvapirat S et al., (2008) designed a new oral controlled release matrix tablet 
based on shellac polymer using metronidazole (MZ) as a model drug. The shellac-
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based matrix tablets were prepared by wet granulation using different amounts of 
shellac and lactose. The effect of annealing temperature and pH of medium on drug 
release from matrix tablets was investigated. The increased amount of shellac and 
increased annealing temperature significantly affected the physical properties (i.e., 
tablet hardness and tablet disintegration) and MZ release from the matrix tablets. The 
in-situ polymerization played a major role on the changes in shellac properties during 
annealing process. Though the shellac did not dissolve in acid medium, the MZ release 
in 0.1 N HCl was faster than in pH 7.3 buffer, resulting from a higher solubility of MZ 
in acid medium. The modulation of MZ release kinetics from shellac-based matrix 
tablets could be accomplished by varying the amount of shellac or annealing 
temperature. The release kinetics was shifted from relaxation-controlled release to 
diffusion-controlled release when the amount of shellac or the annealing temperature 
was increased.  
 
24. Corti G et al., (2008) developed a MH sustained-release formulation in compliance 
with these requirements. The strategy proposed is based on direct-compressed matrix 
tablets consisting of a combination of MH with the hydrophobic triacetyl-b-
cyclodextrin (TAbCD), dispersed in a polymeric material. Different polymers were 
tested as excipients, i.e. hydroxylpropylmethycellulose, xanthan gum, chitosan, ethyl 
cellulose, Eudragit_L100-55, and Precirol_. Release studies demonstrated that blends 
of a hydrophobic swelling polymer (hydroxylpropylmethycellulose or chitosan) with a 
pH-dependent one (Eudragit_L100-55) were more useful than single polymers in 
controlling drug release. Moreover, the main role played by the MH–TAbCD system 
preparation method (i.e. grinding or spray drying) in determining the behaviour of the 
final formulation was evidenced. In particular, the 1:1 (w/w) blend of such systems, 
dispersed in a Eudragit–chitosan polymeric matrix, fully achieved the prefixed goal, 
giving about 30% released drug after 2 h at gastric pH, and overcoming 90% released 
drug within the subsequent 3 h in jejunal fluid.  
 
25. Tanaka N et al., (2005) developed a novel sustained-release (SR) system for poorly 
water soluble drugs by applying solid dispersion (SD) technique for improving the 
solubility. The developed SR system, disintegration-controlled matrix tablet (DCMT), 
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consists of hydrogenated soybean oil (HSO) as wax and SD granules containing low-
substituted hydroxypropylcellulose (L-HPC) as a disintegrant. In this study, nilvadipine 
(NiD) was chosen as a model compound.  
 
Sustained-release profiles of NiD from DCMT were identically controlled in several 
dissolution mediums in spite of varying pH and agitation speed. The release of NiD 
from DCMT was sustained more effectively by increasing the amount of wax or by 
decreasing the amount of disintegrant, and supersaturation of NiD was achieved 
without any re-crystallization in dissolution medium. The release rate of NiD from 
DCMT was controlled by the disintegration rate of tablet. The release profile of NiD 
was described by the Hixson– Crowell’s model better than zero-order kinetics, first-
order kinetics and Higuchi’s model, which supports that the release of NiD from DCMT 
is regulated by the disintegration of the tablet. From this study, it was clarified that 
DCMT was one of the promising SR systems applying SD for the poorly water soluble 
drugs.  
 
26. Jain A et al., (2011) Studied the review on floating drug delivery systems (FDDS) 
was to compile the recent literature with special focus on the principal mechanism of 
floatation to achieve gastric retention. Several approaches are currently utilized in the 
prolongation of the GRT, including floating drug delivery systems (FDDS), also known 
as hydro dynamically balanced systems (HBS), swelling and expanding systems, 
polymeric bio adhesive systems, modified-shape systems, high-density systems, and 
other delayed gastric emptying devices.  From the formulation and technological point 
of view, the floating drug delivery system is considerably easy and logical approach. 
An attempt has been made in this review article to introduce the readers to the 
current technological developments in floating drug delivery System.  
 
27. Thanoo B. C. et al., (2011) Developed Polycarbonate microspheres loaded with 
aspirin, griseofulvin and p-nitroaniline were prepared by a solvent evaporation 
technique. High drug loading (> 50%) was achieved by this process. Drug-loaded 
microspheres were found to float on simulated gastric fluid and intestinal fluid. Drug-
release studies were carried out in these fluids at 37°C. Increasing the drug to polymer 
Arulmigu Kalasalingam College of Pharmacy 
Department of Pharmaceutics   18 
ratio in the microspheres increased both their mean particle size and the release rate 
of the drugs. It was concluded that sustained delivery of drugs could be effected using 
this matrix.  
 
28. Patil P. N et al., (2011) developed as floating drug delivery system (FDDS) for 
sustained release of cisapride using direct compression technology. Core contained 
low density, porous ethyl cellulose, which was coated with an impermeable, insoluble 
hydrophobic coating polymer such as rosin. It was further seal coated with low 
viscosity hydroxypropyl methyl cellulose (HPMC E15) to minimize moisture 
permeation and better adhesion with an outer drug layer. It was found that stable 
buoyant core was sufficient to float the tablet more than 8 h without the aid of sodium 
bicarbonate and citric acid. Sustained release of cisapride was achieved with HPMC 
K4M in the outer drug layer. The floating lag time required for these novel FDDS was 
found to be zero, however it is likely that the porosity or density of the core is critical 
for floatability of these tablets. The in vitro release pattern of these tablets in 
simulated gastric fluid showed the constant and controlled release for prolonged time. 
It can be concluded that the hydrophobic coated buoyant core could be used as FDDS 
for gastro retentive delivery system of cisapride or other suitable drugs.  
 
29. Raja R et al., (2011) developing a modified release hydrogel formulation of poorly 
soluble drug, Gliclazide using a retardant hydrophilic polymer HPMC in two grades i.e., 
HPMC 15 cps and Methocel K4M.  All six formulations were developed and evaluated 
for the in-vitro drug release up to 16hrs and compared with that of the marketed 
formulation. GMF VI was found to have similar release pattern proving to show 
controlled release following zero order release by anomalous diffusion. The similarity 
and Dissimilarity factors were found to be 1.12 and 93.99 respectively.  Thus the 
formulation was found to be advantageous in reducing the dosing intervals and 
enhancing the patient compliance.  
 
 30. Lassalle V et al., (2010) developed Drug delivery systems (DDS) using insulin as 
model drug and poly (lactic–co-glycolic) copolymers (PLGA) as polymeric matrix. The 
carriers were synthesized by direct self-assembly of the insulin and the polyester 
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under mild conditions. In vitro release studies demonstrated that copolyesters of 
about 8600 and 1500 Da were suitable for the gradual release of insulin while PLGA 
oligomers of average molecular weight between 700 and 800 Da were unsuitable as 
DDS. The insulin release kinetics fits well with the Korsmeyer model, following the 
anomalous transport mechanism.  
 
 31. Gupta B. P., (2010)  studied conventional drug delivery systems have slight control 
over their drug release and almost no control over the effective concentration at the 
target site. This kind of dosing pattern may result in constantly changing, 
unpredictable plasma concentrations. Drugs can be delivered in a controlled pattern 
over a long period of time by the controlled or modified release drug delivery systems. 
They include dosage forms for oral and transdermal administration as well as 
injectable and implantable systems. For most of drugs, oral route remains as the most 
acceptable route of administration. Certain molecules may have low oral 
bioavailability because of solubility or permeability limitations. Development of an 
extended release dosage form also requires reasonable absorption throughout the 
gastro-intestinal tract (GIT). Among the available techniques to improve the 
bioavailability of these drugs fabrication of osmotic drug delivery system is the most 
appropriate one. Osmotic drug delivery systems release the drug with the zero order 
kinetics which does not depend on the initial concentration and the physiological 
factors of GIT. This review brings out new technologies, fabrication and recent clinical 
research in osmotic drug delivery.  
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3. AIM AND OBJECTIVE 
 
AIM: 
The aim of the work is to design and develop extended release tablets 
comprising of Metoprolol succinate equivalent to Metoprolol tartrate by wet 
granulation method using swellable polymers such as HPMC K100M, HPMC K4M 
and to carry out the In vitro release study of the drug.  
 
OBJECTIVES: 
 The Pharmaceutical Formulation objectives which were destined to 
achieve during the work are: 
 Extended release tablets with good physical strength. 
 Tablets with optimum content of active pharmaceutical ingredients 
without variation in the content unit/tablet. 
 
The Pharmacological objectives which were destined to achieve during 
the work are: 
 To maintain the drug concentration within the therapeutic range, 
there would be a need of administration of drug for more than once 
a day. 
 To improve the patient compliance and avoid frequency of dosing 
intervals. 
 To provide effective, Safe and stable pharmaceutical oral 
formulation containing Prolonged release of Antihypertension drugs 
with mechanism of action to improve Blood Pressure control.  
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4. PLAN OF WORK 
  
 
 Raw Material Analysis   
 Preformulation studies  
 Compatibility studies   
 Formulation of ER Tablets.   
 Evaluation of Extended Release Tablets.   
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5. DRUG PROFILE 
 
Metoprolol Succinate 
 Metoprolol Succinate is a beta1-selective (cardioselective) adrenoceptor 
blocking agent, for oral administration, available as extended-release tablets. 
Metoprolol Succinate extended-release tablets has been formulated to provide a 
controlled and predictable release of metoprolol for once-daily administration. The 
tablets comprise a multiple unit system containing metoprolol succinate in a 
multitude of controlled release pellets. Each pellet acts as a separate drug delivery 
unit and is designed to deliver metoprolol continuously over the dosage interval. The 
tablets contain 23.75, 47.5, 95 & 190mg of metoprolol succinate equivalent to 25, 50, 
100 & 200mg of metoprolol tartrate USP respectively. This preferential effect is not 
absolute, however and at higher plasma concentrations, metoprolol also inhibits 
beta2-adrenoreceptors, chiefly located in the bronchial & vascular musculature. 
Metoprolol has no intrinsic sympathomimetic activity & membrane-stabilizing activity 
is detectable only at plasma concentrations much greater than required for beta-
blockade. 
 Metoprolol succinate extended-release tablets produced an improvement in 
left ventricular ejection fraction. It was also shown to delay the increase in left 
ventricular end-systolic & end-diastolic volumes after 6 months of treatment. 
 
IUPAC Name        :  1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]- 2-  
Propanol succinate. 
Molecular Weight :  652.8 g/mol. 
Molecular formula :  C15H25NO3 
Therapeutic class :  Hypotension, Angina pectoris, Myocardial Infraction. 
Dose                       :  100mg once daily. 
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PROPERTIES 
Description     :  White coloured crystalline powder. 
Solubility        :  Freely soluble in water, soluble in methanol, sparingly     
        Soluble In ethanol, insoluble in ethyl acetate, acetone, 
                            Diethylether & Heptane.  
Melting point  :  1200C 
Heavy metals  :  Not more than 20ppm 
Sulphated ash  :  Not more than 0.1% 
Loss on drying  :  Not more than 0.5%, determined on 1gm by drying in an  
          Oven at 1050C. 
Storage             :  Store in well-closed container. 
Shelf life      :  36 Months 
 
CLINICAL PHARMACOLOGY 
 Clinical pharmacology studies have confirmed the beta-blocking activity of 
metoprolol in man, as shown by 
 1. Reduction in heart rate & cardiac output at rest upon exercise. 
 2. Reduction of systolic blood pressure upon exercise. 
 3. Inhibition of isoproterenol-induce tachycardia. 
 4. Reduction of reflex orthostatic tachycardia. 
 
Pharmacokinetics 
In man, absorption of metoprolol is rapid and complete. Plasma levels 
following oral administration of conventional metoprolol tablets, however, 
approximate 50% of levels following IV administration, indicating about 50% first-pass 
metabolism. Metoprolol crosses the BBB and has been reported in the CSF in a 
concentration 78% of the simultaneous plasma concentration. Plasma levels achieved 
are highly variable after oral administration. Only a small fraction of the drug (about 
12%) is bound to human serum albumin. Its primarily metabolised by CYP2D6. 
Elimination is mainly by biotransformation in the liver and the plasma half-life ranges 
from approximately 3 to 7 hours. 
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MECHANISM OF ACTION 
1. Competitive antagonism of catecholamine at peripheral (especially cardiac) 
adrenergic neuron sites, leading to decreased cardiac output. 
2. A central effect leading to reduced sympathetic outflow to the periphery. 
3. Suppression of renin activity. 
 
Laboratory test findings 
 Clinical laboratory findings may include elevated levels of serum transaminase, 
alkaline phosphate and lactate dehydrogenase. 
 
Drug Interactions 
Catecholamine depleting drugs (eg, Reserpine, Monoamine oxidase (MAO) 
inhibitors) may have an additive effect when given with beta blocking agents. Observe 
patients treated with Metoprolol succinate extended release tablets plus a 
catecholamine depletory for evidence of hypotension or marked bradycardia, which 
may produce vertigo, syncope or postural hypotension. 
 
Dosage information 
 Overdosage of Metoprolol succinate extended release tablets may lead to 
bradycardia, hypotension & cardiogenic shock. Clinical presentation can also include 
atrioventricular block, heart failure, bronchospasm, hypoxia, impairment of 
consciousness/coma, nausea and vomiting. 
 
Treatment 
 Consider treating the patient with intensive care. Patients with myocardial 
infraction or heart failure may be prone to significant hemodynamic instability. Seek 
consultation with a regional poison control center & a medical toxicologist as needed. 
Beta-blocker overdose may result in significant resistance to resuscitation wit 
adrenergic agents, including beta-agonists. On the basis of the pharmacological 
actions of Metoprolol, employ the following measures. There is very limited 
experience with the use of haemodialysis to remove Metoprolol, however Metoprolol 
is not highly protein bound. 
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6. EXCIPIENT PROFILE 
 
HYDROXY PROPYL METHYL CELLULOSE: 
1. Non-proprietary Names  
BP: Hypromellose, JP: Hypromellose, PhEur: Hypromellose, USP: 
Hypromellose         
2. Synonyms  
Hydroxy propyl methyl cellulose, HPMC, Hypromell sum, Methocel, 
Methyl cellulose propylene glycol ether, Methyl hydroxy propyl cellulose, 
Metolose.  
3. Chemical Name  
Cellulose hydroxyl propyl methyl ether   
4. Functional Category  
Bio adhesive material, coating agent, controlled-release agent, 
dispersing agent, dissolution enhancer,  emulsifying agent, emulsion 
stabilizer, extended-release agent, film forming agent, foaming agent, 
granulation aid, modified-release agent, muco-adhesive, release modifying 
agent, solubilizing agent, stabilizing agent, suspending agent, sustained 
release agent, tablet binder, thickening agent, viscosity-increasing agent.  
5. Applications in Pharmaceutical Formulation or Technology:    
In oral products, hypromellose is primarily used as a tablet binder, film-
coating, and as a matrix for use in extended-release tablet formulations. 
High-viscosity grades may be used to retard the release of drugs from a 
matrix at levels of 10–80%w/w in tablets and capsules.  
6. Description:   
Hypromellose is an odourless and tasteless, white or creamy-white fibrous 
or granular powder.  
7. Typical Properties.  
Acidity/alkalinity pH=5.0–8.0 for a 2%w/w aqueous solution.  
    Ash ≤1.5%   
   Density (bulk) 0.341g/ml  
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   Density tapped) 0.557g/ml  
Melting point: Browns at190–200ºC; chars at 225–230ºC.   
Solubility: Soluble in cold water, forming a viscous colloidal solution.  
POVIDONE K90: 
1.  Non-proprietary Names 
 BP      :    Povidone  
JP   :  Povidone  
PhEur :  Povidone  
USP   :  Povidone  
2. Synonyms  
Kollidon, Plasdone, poly [1-(2-oxo-1-pyrrolidinyl) ethylene], Polyvidone, 
Poly vinyl pyrrolidone, Povidonum, Povipharm, PVP; 1-vinyl-2-
pyrrolidinone polymer.  
3. Chemical Name  
1-Ethenyl-2-pyrrolidinonehomopolymer   
4. Functional Category  
Disintegrant; dissolution enhancer; suspending agent; tablet binder.  
5. Applications in Pharmaceutical Formulation or Technology  
Povidone solutions are used as binders in wet-granulation processes. 
Povidone is also added to powder blends in the dry form and granulated in 
situ by the addition of water, alcohol, or hydro-alcoholic solutions.  
6. Description   
Povidone occurs as a fine, white to creamy white colored, odourless oral 
most odourless, hygroscopic powder.   
7. Typical Properties  
Acidity/alkalinity pH=3.0–7.0 (5%w/v aqueous solution);  
Density (bulk):0.29–0.39g/ml  
Density (tapped):0.39–0.54gml   
Density (true):1.180g/ml  
Melting point often at 150ºC  
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MICROCRYSTALLINE CELLULOSE: 
1.   Non-proprietary  
BP/ JP /USPNF :  Microcrystalline cellulose  
 PhEur   :  Cellulosum microcristallinum  
 
2. Synonyms  
Avicel PH, Celexe, Cellulose gel, Celphere, Ceolus KG, Crystalline cellulose, 
Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, and Vivapur.  
3. Chemical Name   Cellulose.   
4. Description  
Colour    :  White.  
Nature    :  Crystalline powder composed of porous particles.  
5. Typical Properties  
Angle of repose     :  49° for Ceolus KG.  
Density (bulk)       :  0.337 g/cm3.  
6. Functional Category  
Adsorbent, suspending agent, tablet and capsule diluent, tablet 
disintegrant.  
             Applications MCCPpH102 in Pharmaceutical Formulation   
Use  Concentration (%)  
Adsorbent  20–90  
Antiadherent  5–20  
Capsule binder/diluent  20–90  
Tablet disintegrant  5–15  
Tablet binder/diluent  20–90  
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COLLOIDAL SILICON DIOXIDE: 
1. Non-proprietary Names  
BP        :  Colloidal anhydrous silica  
PhEur     :  Silica colloidalis anhydrica  
USPNF  :  Colloidal silicon dioxide  
2. Synonyms  
Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, light anhydrous silicic 
acid, silicic anhydride, silicon dioxide fumed, Wacker HDK.  
3. Chemical Name: Silica  
4. Description  
Colour:  Bluish-White.   
Nature :  Nongritty amorphous, particle size: 15 nm.  
5. Typical Properties  
Acidity/alkalinity:  pH = 3.5–4.4 (4% w/v aqueous dispersion)  
Bulk Density  :  0.029–0.042 g/cm3  
Carr’s index  :  35.52%   
Solubility: Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid, soluble in hot solutions of alkali hydroxide. Forms a colloidal 
dispersion with water.  
6. Functional Category  
Adsorbent, Anticaking agent, Emulsion stabilizer, Glidant, Suspending agent, 
Tablet disintegrant, Thermal stabilizer, Viscosity-increasing agent.  
7. Applications in Pharmaceutical Formulation or Technology  
Aerosols 0.5–2.0%, Emulsion stabilizer 1.0–5.0%, Glidant 0.1–0.5%, Suspending 
and thickening agent 2.0–10.0%.  
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7. MATERIALS AND METHODS 
 
Table No.1 List of Materials and their applications in Formulation  
 
S. 
No 
Name of the materials Manufacturer / Supplier Use in Formulation 
1. Metoprolol Succinate Maan Medex Private, 
Nagpur. 
Active ingredient  
2. HPMC K 100 M Colourcon Asia Ltd, Mumbai. Hydrophilic Polymer 
3. HPMC K 4 M Colourcon Asia Ltd, Mumbai. Hydrophilic Polymer 
4. Lactose Monohydrate Triveni Chemicals, Gujarat. Hydrophilic Polymer 
5. Microcrystalline Cellulose 
PH 102 
Ashutosh Chemicals, Delhi. Hydrophilic polymer 
6. Povidone K – 90 Triveni Chemicals, Gujarat. Binder 
7. Isopropyl Alcohol Arrow Fine Chemical, Rajkot. Binder  
8. Colloidal Silicon Dioxide K.P Manish Global, Chennai. Lubrication 
9. Sodium Stearyl Fumarate Triveni Chemicals, Gujarat. Lubrication 
10. Hypromellose (HPMC E-
05) 
Colourcon Asia Ltd, Mumbai. Coating Material 
11. Titanium Dioxide Shri Krishna Enterprises, 
Chennai. 
Coating Material 
12. Purified Talc Manidharma Biotech Pvt Ltd, 
Chennai. 
Glidant  
13. Tween 80 Triveni Chemicals, Gujarat. Coating Material 
14. Polyethylene glycol – 1500 A.B Enterprises, Mumbai. Coating Material 
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Table No.2 Equipment used for formulation 
 
S. No Equipment Manufacturer / Supplier 
1. Weighing balance-1   Mettler  Toledo, Japan   
2. Dial caliper   Mitutoyo,  Japan   
3. Pfizer Hardness tester   Cadmach, India   
4. Friability tester   Electro lab, Bombay   
5. pH meter   Symchrony, India   
6. Melting point apparatus   Inlab Equipment  pvt.Ltd,  Madras   
7. Hot air oven   Industrial heaters,  chennai   
8. Disintegration apparatus   Electro lab, Mumbai.   
9 Dissolution apparatus   Electro lab, Mumbai.   
10. Ultra-sonic cleaner   Sidilu,  Ultro Sonics, India  
11. UV spectrophotometer – 1700  Shimadzu,  Japan  
12. HPLC   Algient Technologies, Switzerland  
15. 16 Station Compression 
machine   
Cadmach,  India   
16. Stability chamber   Inlay Scientific Instruments, India  
17. Tray Drier   Rays Scientifics instruments, India  
18. Moisture balance  Mettler Toledo,  Japan  
19. Weighing Balance-2  Shimadzu,  Japan   
20. Tab density tester  Electro lab, Mumbai.  
  
7.1 Raw Material Analysis: 
Description    
Appearance of the material was noted compared with specified monograph or 
with standard materials.  
 
Identification 
Identification is the important parameter for Qualitative Analysis of materials. 
Material was identified by chemical and FT-IR method.  
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Solubility Analysis 
Solubility is an important parameter for preformulation studies because:   
1. It affects the dissolution of drug.   
2. Bioavailability of drug is directly affected by dissolution and absorption of 
drug by oral administration.   
3. Particle size, shape, surface area may affects the dissolution characteristics 
of drug hence it should be determined during Preformulation.  
 
Table No.3 Solubility description 
Descriptive Term 
Approximate volume of solute in millilitres per 
gram of solute 
Very Soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000 
Practically insoluble More than 10000 
 
Method: Appropriate quantity of drug was weighed and added to the suitable volume 
of solvent.   
Loss on drying (%)   
1g of drug was accurately weighed and dried in an oven at 105°C for 3 hours. 
By gentle sidewise shaking, the sample was distributed at the specified temperature 
for constant weight.  
The drug sample was allowed to come to room temperature in a desiccator 
before weighing.(69) The difference between successive weights should not be more 
than 0.5mg The loss on drying is calculated by the formula:   
     W3 – W2 
   % LOD = ------------------------- X 100 
     W2 – W1 
 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of Pharmaceutics   32 
Where, W1 – Weight of empty weighing bottle  
         W2 – Weight of weighing bottle + sample  
W3 – Weight of weighing bottle + dried sample  
 
Melting point determination   
The melting point of Active ingredients were determined by capillary method, 
using definite quantity of Active ingredients were taken and placed in apparatus and 
melting point was determined and matched with standards.  
 
Bulk density  
The powder sample (blend) under test was screened through sieve #18 and the 
sample equivalent to 20gm was accurately weighed and filled in a 100ml graduated 
cylinder and the powder was leveled and the unsettled volume (V0) was noted. The 
bulk density was calculated in g/cm3 by the formula,   
Bulk Density = Mass of the Powder / Volume 
 
Purity  
Purity of the sample was analyzed by using suitable method.  
 
7.2 Preformulation Studies 
Preformulation studies are the first step in the rational development of dosage 
form. It is an investigation of physical and chemical properties of a drug substance 
alone and when combined with excipients. Preformulation investigations are 
designed to identify those physicochemical properties and Excipients that may 
influence the formulation design, method of manufacture, and pharmacokinetic-
biopharmaceutical properties of the resulting product. Following are the test 
performed for the preformulation study.  
 
Drug and Drug – Excipient Physical Compatibility Studies:   
The Active ingredients and excipients were mixed and taken in 2 ml glass vials 
and sealed. These glass vials are kept at Room Temperature and 40°C / 75 % RH for 
about 1 month. At the interval of 10 days, the samples were withdrawn and analyzed 
for colour change.   
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Drug and Drug – Excipient Chemical Compatibility Studies:  
The successful formulation of a stable and effective dosage form depends on 
the careful selection of the excipients that are added to facilitate administration, 
promote the consistent release and Bioavailability of the drug and protect it from 
degradation. The excipients are selected by conducting compatibility studies with the 
APIs. 
 
Procedure: 
The APIs were mixed with some of the excipients that can be used for the 
formulation in the ratio of Drug: Excipient (1:1, 1:0.5). These are placed in stability 
chambers at conditions 25°C / 60 % RH and 40°C / 75 % RH for 30 days. The samples 
that were placed in 40°C / 75 % RH chambers were analysed with IR spectroscopy 
after 30 days. For IR studies Shimadzu FTIR (IR Prestige 21) was used. The IR 
spectroscopy graphs obtained were compared with standard graphs. Any possible 
interactions can be detected from changes in graphs of IR studies. The excipient that 
is causing a change will not be used in the formulation. 
 
Containers: 
 Containers and closures for the compatibility study are 10 ml flint glass vials 
(USP type I), Bromo butyl rubber stoppers and tears off clear lacquer 
aluminium seals. 
 Remove vials from packaging and sort out the vials with defects like cracks, 
broken edges, air bubbles and reject them form using. 
 Clean the vials by rising initially with potable water followed by rinsing with 
purified water. 
 Dry the washed vials in hot air oven (70°C for 1 hour). Physically sort the 
washed and dried vials for any kind of defects like broken edges, cracks or air 
bubbles, white or black fibres/particles, foreign matter, etc and reject those 
vials.  
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Sample Preparation: 
 Drug and excipients as per the ratio (1:1, 1:0.5) were prepared and placed with 
accurate amount of drug and excipients in a polybag and mixed. 
 Then these samples were placed in separate flint glass vials. Then these 
samples were charged in stability chamber of conditions 40°C / 75 % RH and 
25°C / 60 % RH. 
 After 15 days and 30 days, samples were also seen for changes in the colour 
and odour (samples placed in both the conditions). 
 
7.3 Formulation Development 
Different batches of Metoprolol succinate Extended release layer (F1to F7) 
were prepared with varying concentrations of different formulation ingredients 
according to Table. Pass the all material in 80 mesh except MCCP pH102 and it was in 
60 mesh. Mix well Metoprolol succinate, polymer, MCCP PH102, CSD then add binder 
solution Isopropyl alcohol to the mixer, Blend well to form a coherent mass and dried 
in oven. And pass the granules in 18 mesh. The granules were lubricated with Sodium 
Stearyl fumarate, Talc and CSD. The amount required for formulation is given for 
following Table.   
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Table No.4 Formula for ER Tablet formulation 
 
Ingredients for 
1 tablet 
F1 
mg 
F2 
mg 
F3 
mg 
F4 
mg 
F5 
mg 
F6 
mg 
F7 
mg 
Metoprolol succinate 95 95 95 95 95 95 95 
HPMC K100M  260 250 240 230 220 210 200 
HPMC K4M - 10 10 20 20 20 20 
Lactose Monohydrate 
(200M) 
80 80 80 80 80 80 80 
Monocrystalline Cellulose 
PH 102 
- - 10 10 20 30 40 
Povidone K-90 15 15 15 15 15 15 15 
Isopropyl Alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
Colloidal Silicon Dioxide 6 6 6 6 6 6 6 
Sodium Stearyl Fumarate 4 4 4 4 4 4 4 
Total Weight 460 460 460 460 460 460 460 
 
Table No.5 Coating Materials ER Tablet Formulation 
Ingredients for 
1 tablet 
F1
mg 
F2
mg 
F3
mg 
F4
mg 
F5 
mg 
F6 
mg 
F7
mg 
Hypromellose 9.5 9.5 9.5 9.5 9.5 9.5 9.5
Titanium Dioxide 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Purified Talc 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Tween 80 1.25 1.25 1.25 1.25 1.25 1.25 1.25
Polyethylene glycol-1500 0.75 0.75 0.75 0.75 0.75 0.75 0.75
Brilliant blue lake 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Isopropyl Alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Methylene chloride Q.S Q.S Q.S Q.S Q.S Q.S Q.S
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MANUFACTURING PROCESS: 
1. Shifting: 
 Pass the ingredients through the below mentioned mesh size and collect 
separately. 
Table No.6 Sieving process 
S.NO Ingredients Mesh size Microns 
1. Metoprolol succinate 30# 600 
2. HPMC K100M 20# 840 
3. HPMC K4M 20# 840 
4. Lactose Monohydrate 60# 250 
5. MCC PH 102 40# 420 
6. CSD 30# 600 
7. Sodium Stearyl fumarate 40# 420 
 
2. Dry Mixing: 
 Load the sifted batch quantity materials in to the RMG by following sequence 
Metoprolol succinate, HPMC K100M, HPMC K4M, Lactose monohydrate and 
Microcrystalline Cellulose PH 102. Mix the materials by running impeller at slow speed 
for 10 minutes and chopper off. 
 
3. Isopropyl Alcohol: 
 Take 50.0kg of Isopropyl alcohol in SS vessel and slowly disperse Povidone K 
90 in to it and stir well. Care should be taken while adding PVP K90 to avoid lump 
mass. 
 
4. Granulation: 
 Add the binder solution slowly to the materials of dry mixing with impeller at 
slow speed and chopper off. Mix the wet mass for 1 minute with impeller slow and if 
require use chopper at slow speed. If require add extra quantity of Isopropyl alcohol 
with impeller at slow speed and impeller off NMT 1.5Kg of Isopropyl alcohol at a time 
within a period of 1-2 minutes. Every addition of Isopropyl alcohol mix for one minute, 
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impeller slow or high speed and adjust chopper speed slow or high to get the required 
granules size (20#). 
 
5. Drying and Milling: 
 Load the wet granules into FBD and air dry the granules until no odour of 
isopropyl alcohol. Set the temperature as follow as for temperature drying. 
  Inlet temperature:   55 ± 50C 
  Outlet temperature:   40 ± 50C 
Dry the wet granules till to reach LOD between 1.75 – 3.0 % at 1050C. Perform the 
intermittent raking. Note the temperature for every 15 minutes. Sieve the dried 
granules through 20#. Mill the retained granules through multi mill fitted with 1.0 mm 
screen until pass through 20#. Whenever checking the LOD, note the outlet 
temperature.  
 
6. Blending: 
 Load above dried granules and sifted materials of colloidal silicon dioxide into 
Double cone blender and allow mixing for 10 minutes at high speed. 
 
7. Lubrication:  
 To the above blended granules add sifted batch quantity of sodium Stearyl 
fumarate to the above blend and mix for 5 minutes. Send the sample to QC for 
complete analysis bulk, tap density, particle size distribution and assay analysis. 
 
8. Compression: 
Upper punch: 14/32 (11.11mm) Circular shape, standard biconcave punch. 
Lower punch: 14/32 (11.11mm) Circular shape, standard biconcave punch. 
Compress the lubricated blend using above set punches and send the sample 
to QC for complete analysis as per current USP specification. After getting the QC 
report, start the compression and maintain the physical parameters within the 
specified limit. 
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7.4 Evaluation of Compressed Tablet 
7.4.1 Description: 
 Blue coloured, Circular shaped, biconvex, film coated tablets having plain 
surface on both sides. 
 
7.4.2 Weight Variation: 
Weigh individually 20 tablets taken at random and determine the average 
weight. Not more than 2 of the individual weight deviate from the average weight. 
The percentage deviation shown in Table No.7.    
 
Table No.7 Limits for Weight Variation 
Average weight of tablet  Percentage deviation  
80 mg or less  10 
More than 80 mg but less than 250 mg  7.5 
250 mg or more  5 
 
7.4.3 Thickness: 
It can be dimensionally described & controlled. Thickness may affect the 
hardness, disintegration time and dissolution rate.  Tablet thickness can be measured 
by caliper for six tablets.  
 
7.4.4 Diameter:  
It also dimensionally described & controlled. Tablet diameter can be measured 
for six tablets by Dial calliper. 
 
7.4.5 Friability: 
It is expressed in percentage.  Take a sample of whole tablets corresponding 
as near as possible to 6.5 gm. For tablets with a unit mass of more than 650 mg, take 
a sample of 10 whole tablets. The tablets are carefully dedusted prior to testing. 
Accurately weigh the tablet sample (Winitial)   and place the tablets in the drum. Rotate 
Arulmigu Kalasalingam College of Pharmacy 
Department of Pharmaceutics   39 
the drum 100 times at the rate of 25±2 rpm and remove the tablets. Remove any loose 
dust from the tablets as before, and accurately weigh (Wfinal).  
                                    (Winitial-Wfinal)  
       % F =   ----------------------- X 100   
                                      (Winitial)  
 
7.4.6 Tablet Disintegration time: 
Tablet disintegration study was performed only for immediate release tablet 
and for the immediate release layer of inlay tablet. Disintegration time was 
determined using USP tablet disintegration tester in distilled water.  
 
7.4.7 Assay: (USP Monograph) 
 Determine the mean percentage value of the labelled amount of Metoprolol 
succinate from the tablets analysed in the test for Uniformity of Dosage Units. 
Acceptance Criteria: 90.0mg to 110.0mg (90.0% to 110.0% of label claim) 
 
7.4.8 Uniformity of Dosage Units: (USP Monograph) 
Chromatographic Conditions: 
 Column  : C8 [4.0 mm X 12.5 cm, 5 µm] (L7) 
 Flow rate  : 1.0ml/minute 
 Pump mode  : Isocratic 
 Wavelength  : 280nm 
 Injection Volume : 40 µL 
 
Preparation of 1 M Monobasic sodium phosphate: 
 Weigh about 13.8 gm of monobasic sodium phosphate and transfer into 100 
ml volumetric flask, dissolve and dilute up to the volume with water. 
 
Preparation of 1 M Phosphoric acid: 
 Transfer 6.6 ml of phosphoric acid through pipette into 100 ml volumetric 
flask, dilute up to the volume with water. 
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Preparation of Buffer: 
 Mix 50 ml of 1 M monobasic sodium phosphate and 8.0 ml of 1 M phosphoric 
acid, dilute with water to 1000 ml. If, necessary adjust with 1M monobasic potassium 
phosphate or 1 M phosphoric acid to a pH of 3.0. 
 
Mobile Phase: 
 Prepare a mixture of 250 volumes of Acetonitrile and 750 volumes of buffer 
solution. Mix and filter the solution through 0.45 µm nylon filter and sonication was 
done for 10 minutes. 
 
Preparation of Standard Solution: 
 Weigh accurately 50 mg of Metoprolol succinate working standard and 
transfer into a 100 ml volumetric flask, add 50 ml of mobile phase and sonicate for 5 
minutes to dissolve. Cool & dilute up to the volume with mobile phase. Transfer 5 ml 
of the above solution through pipette into a 50 ml volumetric flask & dilute up to the 
volume with mobile phase. Filter the solution through 0.45 µm nylon & collect the 
solution in an HPLC vial after discarding about first 2 ml of filtrate. 
 
Preparation of Sample Solution: 
 Transfer one tablet into a 100 ml volumetric flask, add about 5 ml of water, 
and allow the tablet to disintegrate & add 30 ml alcohol & shake for 30 minutes. Add 
50 ml of 0.1 N HCl to the flask, and shake for additional 30 minutes. Dilute up to the 
volume with 0.1 N HCl. Transfer 5 ml of the above solution into a 100 ml volumetric 
flask & dilute up to the volume with mobile phase. Filter the solution through 0.45 µm 
nylon & collect the solution in an HPLC vial after discarding about first 2 ml of filtrate. 
 
Acceptance Criteria:  
The acceptance value of the first 10 dosage units should be less than or equal 
to L1=15.0. 
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7.4.9 In-vitro Dissolution studies: (USP Monograph) 
Dissolution Parameters: 
 Medium : pH 6.8 Phosphate buffer 
 Volume : 500 ml 
 Apparatus : USP Type – II (Paddle) 
 Time  : 1st, 4th, 8th, and 20th hour. 
 Speed  : 50 RPM 
 Temperature : 36.50C to 37.50C 
 
Preparation of 0.2 M sodium hydroxide: 
 Weigh and dissolve 0.8 gm of sodium hydroxide in 100 ml of water. 
 
Preparation of Dissolution medium: 
 Dissolve 6.8 gm of monobasic potassium phosphate and 0.9 gm of sodium 
hydroxide in 1000 ml of water. Adjust the pH to 6.80 ± 0.1 with 0.2 M sodium 
hydroxide. 
 
Chromatographic Conditions: 
 Column  : C8 [4.0 mm X 12.5 cm, 5 µm] (L7) 
 Flow rate  : 1.0ml/minute 
 Pump mode  : Isocratic 
 Wavelength  : 280nm 
 Injection Volume : 40 µL 
 
Preparation of 1 M Monobasic sodium phosphate: 
 Weigh about 13.8 gm of monobasic sodium phosphate and transfer into 100 
ml volumetric flask, dissolve and dilute up to the volume with water. 
 
Preparation of 1 M Phosphoric acid: 
 Transfer 6.6 ml of phosphoric acid through pipette into 100 ml volumetric 
flask, dilute up to the volume with water. 
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Preparation of Buffer: 
 Mix 50 ml of 1 M monobasic sodium phosphate and 8.0 ml of 1 M phosphoric 
acid, dilute with water to 1000 ml. If, necessary adjust with 1M monobasic potassium 
phosphate or 1 M phosphoric acid to a pH of 3.0. 
 
Mobile Phase: 
 Prepare a mixture of 250 volumes of Acetonitrile and 750 volumes of buffer 
solution. Mix and filter the solution through 0.45 µm nylon filter and sonication was 
done for 10 minutes. 
 
Preparation of Standard Solution: 
 Weigh accurately 50 mg of Metoprolol succinate working standard and 
transfer into a 100 ml volumetric flask, add 50 ml of mobile phase and sonicate for 5 
minutes to dissolve. Cool & dilute up to the volume with mobile phase. Transfer 5 ml 
of the above solution through pipette into a 50 ml volumetric flask & dilute up to the 
volume with mobile phase. Filter the solution through 0.45 µm nylon & collect the 
solution in an HPLC vial after discarding about first 2 ml of filtrate. 
 
Preparation of Sample Solution: 
 Follow the dissolution parameters as mentioned in the above. After 
completion of specified different time intervals in dissolution test, collect 10.0 ml of 
sample solution in the middle of each dissolution jar & replace with 10.0 ml of 
dissolution medium after each withdrawal of the sample. Transfer 5 ml of the above 
solution through pipette into 20 ml volumetric flask & dilute up to the volume with 
dissolution medium. Filter the solution through 0.45 µm nylon & collect the solution 
in an HPLC vial after discarding about first 2 ml of filtrate. 
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Acceptance Criteria: 
Time interval (hours) Amount dissolved (%) 
1st hour Not more than 25 % 
4th hour 20.0 % - 40.0 % 
8th hour 40.0 % - 60.0 % 
20th hour Not less than 80.0 % 
 
Data analysis: 
The data obtained from the dissolution study were subjected for analysis to 
know the release pattern of the drug from the dosage form. To analyse the 
mechanism of release and release rate kinetics of the dosage form, the data obtained 
were fitted into Zero order, First order, Higuchi model and Korsmeyer-Peppas model. 
Based on the r-value, the best-fit model was selected. 
 
Zero order kinetics: 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate 
and release the drug slowly, assuming that the area does not change and no 
equilibrium conditions are obtained can be represented by the following equation, 
   Q t = Q o + K o t  
Where   Q t = amount of drug dissolved in time t. 
             Q o = initial amount of the drug in the solution 
             K o = zero order release constant. 
 
First order kinetics: 
To study the first order release rate kinetics, the release rate data were fitted 
to the following equation, 
  Log Q t = log Q o + K1t/2.303 
Where   Q t is the amount of drug released in time t, Q o is the initial amount of drug 
in the solution and K1 is the first order release constant. 
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Higuchi model: 
To study the Higuchi release kinetics, the release rate data were fitted to the 
following equation, 
  F = K.t1/2 
 Where ‘F’ is the amount of drug release,’ K’ is the release rate constant and‘t’ is the 
release time. When the data is plotted as a cumulative drug released versus square 
root of time, yields a straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to ‘K’. 
 
Korsmeyer – Peppas release model: 
The release rate data were fitted to the following equation, 
   M t 
        ------------   = K.tn  
               M ∞ 
 
Where, M t / M ∞ is the fracƟon of drug release, ‘K’ is the release constant, ‘t’ is the 
release time and ‘n’ is the diffusion exponent for the drug release that is dependent 
on the shape of the matrix dosage form. When the data is plotted as Log fraction of 
drug released versus Log time, yields a straight line with a slope equal to ‘n’ and the 
‘K’ can be obtained from Y – intercept. 
 
Diffusion exponent (n)  Overall solute diffusion mechanism  
0.45  Fickian diffusion  
0.45< n<0.89  Anomalous (non-Fickian) diffusion  
0.89  Case-II transport  
n>0.89  Super case-II transport  
 
i. Zero Order Reaction -% Cumulative drug release Vs Time in hrs   
ii. First Order Reaction – Log % Cumulative drug remaining Vs Time in hrs   
iii. Higuchi kinetics -% Cumulative drug release Vs square root of time   
iv. Korsmeyer – Pappas equation -log cumulative % of drug released Vs log 
time   
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Blister Packing of Dosage form 
Packing of dosage forms is important for reasons like  
 Protection 
 Identification 
 Elegance 
 Ease of Shipping 
Blister packing is done for the selected formulation before being for the 
stability studies. 
 
Packaging of Tablets: 
Base foil and lidding foil were loaded in the machine. The tablets were loaded 
in the hopper. The base foil passes through the forming units with Teflon heads and 
cavities are formed. Tablets in the hopper coming down through inclined feeding 
channel and singling unit and are introduced into the cavities formed. The lidding foil 
introduced and the sealing of the foils was done in the sealing station. The non-filled 
cavities are detected using non fill detecting system and are rejected by non- filling 
detection rejection area. The cutting assembly and the trimming station cuts the 
blister into appropriate size. 
 
STABILITY STUDIES 
Introduction: 
In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date 
of manufacture and the packaging of the formulation, until its chemical or biological 
activity is not less than a predetermined level of labelled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
 
Objective of the Study: 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
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environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. 
  The International Conference on Harmonization (ICH) Guidelines titled 
“Stability Testing of New Drug Substance and Products” (QIA) describes the stability 
test requirements for drug registration applications in the European Union, Japan and 
the United States of America. ICH specifies the length of study and storage conditions. 
Accelerated Testing: 400C ± 20C/75 % RH ± 5 % RH for 6 Months. 
 
Method: 
Stability studies were carried out at 400C / 75 % RH for 6 months for the 
selected formulation. This formulation was selected because of its reproducibility of 
the In-vitro drug release of the drug from the extended release tablets. The 
formulation was charged for stability at conditions 400C / 75 % RH which are usually 
conditions for the Real time and Accelerated stability study. The formulation was 
tested for parameters like appearance, assay, uniformity of weight, In-vitro drug 
release. 
 
Formulation Stability Condition Testing Frequency Tested For 
Selected 
Formulation 
400C / 75 % RH 1st month 
2nd month 
3rd month 
6th month 
Appearance, Assay, 
Uniformity of weight,  
In-vitro drug release   
 
 
 
 
 
 
 
 
 
 
  
 
 
RESULTS AND DISCUSSION 
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8. RESULTS AND DISCUSSION 
 
Raw Material Analysis: 
Solubility: 
 Metoprolol succinate was found to be freely soluble in water, soluble in 
methanol, sparingly soluble in ethanol, slightly soluble in dichloromethane and 2-
propanol, insoluble in ethyl acetate, acetone diethyl ether and heptane. 
 
Loss on Drying: 
Loss on drying was determined and the results are illustrated.  
Drug Specification Observation 
Metoprolol succinate Not more than 0.5%  0.2% ± 0.5334  
The Loss on Drying for the drugs are within pharmacopoeial limits  
 
Melting point of drug:   
The melting point of Active ingredient was determined by capillary method. 
Drug Specification Observation 
Metoprolol succinate 1200C 119.50C 
 
PREFORMULATION STUDIES:   
The overall objective of preformulation studies is to generate useful 
information to the formulator in developing stable and bioavailable dosage forms that 
can be mass produced.   
 
Physical Drug-excipient Compatibility studies:   
The successful formulation of a stable and effective solid dosage form depends 
on the careful selection of the excipients that are added in the formulation. The drug 
and excipients must be compatible with one another to produce a product that is 
stable, Efficacious and easy to administer and safe.   
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The physical compatibility evaluation was performed in visual basis. The study 
implies that the drug, polymer and other excipients were physically compatible with 
each other as there was no change of physical description. 
 
Drug and Drug – excipient Chemical Compatibility studies: 
The samples that were charged in 450C/75% RH stability chambers were 
analysed by IR spectroscopy after 30 days. The graphs of the samples were given 
below: 
 
 
Figure 2 Infra-red spectra of pure drug Metoprolol succinate 
 
 
Characteristic peaks of pure Metoprolol succinate 
S.No 
Type of 
bond 
Type of 
vibration 
Actual 
frequency 
(cm-1) 
Observed 
frequency 
(cm-1) 
Confirmation 
1 C=C Stretching ͠    1600 1614.95 Aromatic 
2 N-H Stretching 3310-3140 3148.91 20 amine 
3 C-O Stretching 1350-1260 1271.04 20 alcohol 
4 C-O Stretching 1150-1070 1148.45 Ether 
5 C-O Stretching 1410-1300 1385.99 Phenoxide 
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Figure 3 Infra-red spectra of Metoprolol succinate + HPMC K100M 
 
Characteristic peaks of Metoprolol succinate in mixture of drug + HPMC K100M 
S.No 
Type of 
bond 
Type of 
vibration 
Actual 
frequency  
(cm-1) 
Observed 
frequency 
(cm-1) 
Confirmation 
1 C=C Stretching ͠    1600 1615.17 Aromatic 
2 N-H Stretching 3310-3140 3161.26 20 amine 
3 C-O Stretching 1350-1260 1271.08 20 alcohol 
4 C-O Stretching 1150-1070 1148.62 Ether 
5 C-O Stretching 1410-1300 1386.54 Phenoxide 
 
 
Figure 4 Infra-red spectra of Metoprolol succinate + HPMC K4M 
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Characteristic peaks of Metoprolol succinate in mixture of drug + HPMC K4M 
 
S.No 
Type of 
bond 
Type of 
vibration 
Actual 
frequency 
(cm-1) 
Observed 
frequency 
(cm-1) 
Confirmation 
1 C=C Stretching ͠    1600 1615.57 Aromatic 
2 N-H Stretching 3310-3140 3152.05 20 amine 
3 C-O Stretching 1350-1260 1270.48 20 alcohol 
4 C-O Stretching 1150-1070 1147.11 Ether 
5 C-O Stretching 1410-1300 1386.41 Phenoxide 
 
 
Figure 5 Infra-red spectra of Metoprolol succinate + HPMC K100M + HPMC K4M 
 
Characteristic peaks of Metoprolol succinate in mixture of drug + HPMC K 100M + 
HPMC K 4M 
S.No 
Type of 
bond 
Type of 
vibration 
Actual 
frequency 
 (cm-1) 
Observed 
frequency 
(cm-1) 
Confirmation 
1 C=C Stretching ͠    1600 1615.54 Aromatic 
2 N-H Stretching 3310-3140 3169.47 20 amine 
3 C-O Stretching 1350-1260 1271.00 20 alcohol 
4 C-O Stretching 1150-1070 1148.03 Ether 
5 C-O Stretching 1410-1300 1386.47 Phenoxide 
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Discussion: 
From the IR studies and Physical observation it can be concluded that there 
will be no possible chemical interaction between the excipients and the drugs. So 
these excipients were used for the formulation. 
There is no appearance or disappearance of any characteristic peaks. This 
shows that there is no interaction between the drug and polymer used. 
 
Weight variation  
The theoretical Average weight of the various formulated tablets are 475mg 
and weight variation of the various formulation are depicted in the Table No.8. The 
percentage deviation of the weight was within 5% as per monograph.   
 
Hardness  
The hardness of the various tablet formulation was shown in Table No.8. The 
hardness tablet found in the ranges from 5.91 to 6.8. So, it was the sufficient hardness 
for tablet, coating, transporting, and packing.   
 
Table No.8 Physical Parameters of Extended Release Tablets 
Formulation 
Weight 
variation** 
Hardness* Thickness* Friability* Diameter* 
Drug 
content* 
F1 470.5±19.59  6.08±0.491  6.48±0.113  0.200±.102  13.11±0.006  101.23±0.05  
F2 473.3±7.97  5.91±0.376  6.42±0.214  0.176±0.071  13.10±0.007  101.53±0.06  
F3  465.3±6.76  6.66±0.516  6.61±0.063  0.245±0.176  13.10±0.005  102.04±0.01  
F4  472.4±10.9  6.41±0.204  6.63±0.017  0.103±0.045  13.11±0.004  103.21±0.04  
F5  470.0±1.63  6.33±0.258  6.62±0.082  0.107±0.025  13.10±0.008  99.71±0.04  
F6 472.1 ±1.72  6.41±0.204  6.52±0.129  0.113±0.019  13.10±0.005  99.43±0.04  
F7  474.5±0.59  6.25±0.273  6.50±0.064  0.123±0.014  13.10±0.006  101.38±0.01  
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Thickness  
The thickness of the various tablet formulation was shown in the above Table 
No.8. The thickness of the tablet found in the ranges from 6.42 to 6.63. It was 
important for packing of tablet and acceptance.  
 
Friability  
The friability of the various tablet formulation was shown in the above Table 
No.8. The friability of the tablet found in the ranges from 0.1 to 0.2.  The values are 
within limit of the official monograph.  
 
Diameter  
The diameter of the tablet found in the ranges from 13.1 to 13.11. It was 
important for packing of tablet and acceptance. The diameter of the various tablet 
formulation was shown in the above Table No.8.  
 
Drug content  
The content of the various formulation was analyzed by High Performance 
Liquid Chromatography method. It was very important for the release percentage 
from the amount present in the tablet. The percentage of drug fount in the ranges 
from 99.43 to 103.21.  The drug content of various formulation was shown in the 
above Table No.8.  
 
Table No.9 In vitro Dissolution profile Extended Release tablet 
Time in hrs 1 4 8 20 
F1  52.92±1.367   73.73±1.108  85.25±1.222   94.05±0.799  
F2  48.95±0.399  61.21±0.385  82.16±0.887  90.71±1.391  
F3  40.54±1.41  53.71±0.804  72.55±1.188  83.66±0.989  
F4  26.75±0.947  43.78±0.817  58.64±1.515  71.36±0.904  
F5  20.17±0.782  40.99±0.572  62.56±0.718  95.52±0.56  
F6 19.87±0.862  35.60±0.439  49.98±1.002  94.12±0.51  
F7 16.73±0.685  30.38±1.391  52.80±0.3416  94.35±1.456  
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In vitro dissolution release profile of various formulation studied. From the 
results of in vitro Dissolution studies of Extended Release formulations it was 
observed that the formulation F1 to F7. Formulation F4 having a release profile up to 
12 hours was selected for formulation of ER tablet. It was concluded that the drug 
release from the hydrophilic polymer HPMC K100M shows the better release rate. The 
concentration of polymers respect to the drug was 40%w/w. So, the polymer 
concentration increase the release time also increases. All the polymer showed the 
sustained release property.  
 
Drug release comparison of optimized batch with pure drug sample (API): 
Chromatogram study: 
The optimized batch of formulation drug release was gradually increases with 
time (fig 7, 8, 9, 10) at 1st, 4th, 8th, 20th hour. The 20th hour chromatogram of the 
optimized formulation (F7) was MATCH with the chromatogram of the pure drug 
sample (API) at 0 hour (fig 6). 
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Fig 6 Dissolution Standard Chromatogram 
 
 
 
 
Fig 7 Dissolution Test for 1st Hour 
 
 
 
 
Fig 8 Dissolution Test for 4th Hour 
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Fig 9 Dissolution Test for 8th Hour 
 
 
 
 
Fig 10 Dissolution Test for 20th Hour 
 
 
 
Fig 11 Standard Chromatogram for Uniformity of Content 
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Fig 12 Sample Chromatogram for Uniformity of Content 
 
 
 
Kinetic Study: 
Formulation – 7 was found to be giving the desired in vitro dissolution rate, so 
this formulation was selected for determining the nature of release of drug from 
dosage form. 
Formulation 
Zero-order 
kinetics 
First-order 
kinetics 
Higuchi’s 
kinetics 
Korsmeyer-
Peppas 
Formulation - 7 
Slope R2 Slope R2 Slope R2 Slope R2 
8.425 0.786 0.227 0.996 31.65 0.964 -0.406 0.954 
 
The curve fitting results of the release rate profile of the designed formulations 
gave an idea on the mechanism of drug release. Based on the data analysis the drug 
release was found to follow First order kinetics, the drug release mechanism was best 
explained by first order, as the plots showed the highest linearity. This model indicates 
a coupling of the diffusion and erosion mechanism (Anomalous diffusion) and 
indicates that the drug release was controlled by more than one process. 
 
Stability Study Data: 
The samples from the stability chambers that were packed in PVC Blister 
packing were subjected to following analysis. 
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Parameter Specifications Initial 
1st month at 
400C/ 75% RH 
Appearance Blue colour, Circular 
shaped, biconvex film 
coated tablets having 
plain surface on both 
sides. 
Complies Complies 
Average weight of 20 
tablets 
475.00mg ± 3.0% 477.86mg 476.34mg 
Weight variation ±3.0% -0.59% to + 
0.50% 
-1.02% to +1.20% 
Assay: 
Each film coated tablet 
contains, 95mg 
Metoprolol Succinate USP 
is equivalent to 100mg of 
Metoprolol Tartrate USP  
90.00 % to 110.00 % of 
label claim (85.50mg to 
104.50mg of Metoprolol 
Succinate) 
100.64% of 
label claim 
(95.82mg of 
Metoprolol 
Succinate) 
100.03% of label 
claim (95.01mg 
of Metoprolol 
Succinate) 
In-Vitro drug release 
profile 
1st hour NMT 25.00% 16.73% 16.06% 
4th hour 20.00% to 
40.00% 
30.38% 30.42% 
8th hour 40.00% to 
60.00% 
52.80% 53.14% 
20th hour NLT 80.00% 94.35% 95.42% 
 
 
 
 
 
 
 
  
 
 
 
 
 
SUMMARY AND CONCLUSION 
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9. SUMMARY AND CONCLUSION 
 
The Present research endeavour is directed towards the development of once 
daily extended release matrix Tablet of Metoprolol succinate equivalent to 
Metoprolol Tartrate 100mg.   
The different concentration of polymer was used to control the drug release 
from the dosage form (USP Monograph limits). 
This extended release tablet is effective in improving the hypertension control 
by blocking the beta2 adrenergic receptors. Matrix System was based on swellable 
polymer were selected for sustaining the drug release. Different polymers to get the 
desired release profile over a period for 20 hours. Different batches of extended 
release was prepared by Wet granulation Method respectively.  
All the formulations were evaluated for physical characteristics, disintegration, 
in vitro dissolution study and stability. Following conclusions have been made from 
the present study.   
  
 The physical characteristics of all the blended formulations were satisfactory.   
 The prepared tablets evaluated for Assay, weight variation, hardness, 
thickness and friability and Disintegration time were found to be within the 
official limits.   
 The in vitro dissolution studies were performed for all the ER formulations.  
 In Vitro Dissolution study of ER formulations F7 showed release profile were 
complies with USP at 40% concentration of HPMCK100M with respect to drug 
compared with another 6 formulation.  
 In-vitro Dissolution study of ER Tablets was compared to the API.  
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